Breaking News
EG4 Power Pro VS Ruixu Lithi VS Yixiang Budget Battery! Best Selling Battery Showdown!
When Society Breaks: The Human Threats You'll Face in a Real SHTF Collapse
Dubai-Based Emirates Airline Adds Bitcoin and Crypto Payments
Oh My F#@!ing God, They're Doing It Again
Top Tech News
What could possibly go wrong? Scientists use AI to design new viruses
Dual-motor suitcase drive underpins 3,000-hp hypercar
DoorDash Wins Federal Approval To Fly Its Own Delivery Drones
Shade-Resistant Solar Cells Retain 97% Efficiency After 2,000 Hours of Testing
20 Ancient Engineering SECRETS
Stonehenge Was Reanalyzed by AI -- And the Findings Are Hard to Explain
After Years Of Delays, Aptera Is Finally Preparing To Build Customer Cars
'When you kill it, it doesn't die': the jellyfish that has cracked the secret of immorta
Archer Aviation debuts Halo autonomous VTOL, Thunder's commercial twin
US Telecoms Slide On Starlink Mobile Threat; Bernstein Sees It As A "Jab, But No Knockout Yet**
Trump/Kennedy FDA Approves Moderna mRNA-1010 Influenza Shot 'mFLUSIVA'...
FDA approved the injection for seniors before any clinical benefit was shown, and before confirming vaccinated can't shed vaccine components onto unvaccinated, raising informed consent concerns.
Yesterday, Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) has "approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older."
Even though the alleged benefit for adults 65 and older was never proven.
The move comes after the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously in June that the "benefits" of Moderna's experimental mRNA influenza vaccine "outweigh its risks."
It also comes after President Trump selected a military-grade influenza pandemic architect, Erica Schwartz, to run the CDC.
Moderna expects to have the drug available for eligible populations in the U.S. for the 2026-2027 respiratory virus season.